The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue 3, 1998, Pages 357-366

  Siau, Hong ^a,b   Kerridge, David ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CHLORTETRACYCLINE; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; RIFAMPICIN; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; DRUG ANTAGONISM; DRUG POTENTIATION; FUNGUS CULTURE; FUNGUS GROWTH; NONHUMAN; SACCHAROMYCES CEREVISIAE;

AGAR; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CELL DIVISION; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUCYTOSINE; HUMANS; MICONAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 0031954527     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.3.357     Document Type: Article

References (36)

1. Edwards, J. E. (1991). Invasive Candida infections. Evolution of a fungal pathogen. New England Journal of Medicine 324,1060-2.
2. Nguyen, M. H., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L, Syndman, D. R. et al. (1996). The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. American Journal of Medicine 100, 617-23.
3. Georgopapadakou, N. H. & Walsh, T. J. (1996). Antifungal agents: chemotherapeutic targets and immunologie strategies. Antimicrobial Agents and Chemotherapy 40,279-91.
4. Graybill, J. R. (1996). The future of antifungal therapy. Clinical InfectiousDiseasesZ2, Suppl. 2, S166-78.
5. Polak, A. (1988). Combination therapy with antifungal drugs. Mycoses 31, Suppl. 2, 45-53
6. Medoff, G., Comfort, M. & Kobayashi, G. S. (1971). Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proceedings of the Society of Experimental Biology & Medicine 138,571-4.
7. Shadomy, S., Wagner, G., Espinel-lngroff, A. & Davis, B. A. (1975). In-vitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrobial Agents and Chemotherapy 8, 117-21.
8. Graybill, J. R., Williams, D. M., van Cutsem, E. & Drutz, D. J. (1980). Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Reviews in Infectious Diseases 2,551-8.
9. Dupont, B. & Drouhet, E. (1979). In-vitro synergy and antagonism of antifungal agents against yeast-like fungi. Postgraduate MedicalJournalSS, 683-6
10. Martin, E., Maier, F. & Bhakdi, S. (1994). Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrobial Agents and Chemotherapy 38,1331-8.
11. Vazquez, J. A., Arganoza, M. T., Vaishampayan, J. K. & Akins, R. A. (1996). In-vitro interaction between amphotericin B and azoles in Candida albicans. Antimicrobial Agents and Chemotherapy 40, 2511-6.
12. Polak, A., Scholer, H. J. & Wall, M. (1982). Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. ChemotherapyZB, 461-79.
13. Nguyen, M. H., Barchiesi, F., McGough, D. A., Yu, V. L & Rinaldi, M. G. (1995). In-vitro evaluation of combination of fluconazole and 5-fluorocytosine against Cryptococcus neoformans var. neoformans. Antimicrobial Agents and Chemotherapy 39, 1691-5.
14. Ghannoum, M. A., Fu, Y., Ibrahim, A. S., Mortara, L. A., Shafiq, M. C., Edwards, J. E. ef at. (1995). In-vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrobial Agents and Chemotherapy 39, 2459-65.
15. Tariq, V. N., Scott, E. M. & McCain, N. E. (1995). Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro. Antimicrobial Agents and Chemotherapy 39,2615-9.
16. Odds, F. C. (1982). Interactions among amphotericin B, 5-fluorocytosine, ketoconazole and miconazole against pathogenic fungi in vitro. Antimicrobial Agents and Chemotherapy 22, 763-70.
17. Van der Auwera, P., Ceuppens, A. M., Heymans, C. & Meunier, F. (1986). In-vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations. Antimicrobial Agents and Chemotherapy 29, 997-1004.
18. Ghannoum, M. A., Motawy, M.S., Abu Hatab, M. A., Ibrahim, A. S. & Griddle, R. S. (1989). Multifactorial analysis of effects of interactions among antifungal and antineoplastic drugs on inhibition of Candida albicans growth. Antimicrobial Agents and Chemotherapy 33, 717-25.
19. Beggs, W. H. & Sarosi, G. A. (1982). Combined activity of ketoconazole and 5-fluorocytosine on potentially pathogenic yeasts. Antimicrobial Agents and Chemotherapy 21, 355-7.
20. Petrou, M. A. & Rogers, T. R. (1991). Interactions in vitro between polyenes and imidazoles against yeast. Journal of Antimicrobial Chemotherapy 27,491-506.
21. Edwards, J. E., Morrison, J., Henderson, D. K. & Montgomerie, J. Z. (1980). Combined effect of amphotericin B and rifampicin on Candida species. Antimicrobial Agents and Chemotherapy 17, 484-7.
22. Van der Auwera, P. & Meunier-Carpenter, F. (1983). In-vitro study of amphotericin B plus rifampicin on Candida species. In Proceedings of the Second International Symposium on Infections in the Immunocompromised Host (Easmon, C. S. F. & Gaya, H., Eds), pp. 346-9. Academic Press, London.
23. Brajtburg, J., Kobayashi, D., Medoff, G. & Kobayashi, G. S. (1982). Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics. Journal of Infectious Diseases 146,13816.
24. Sud, I. J. & Feingold, D. S. (1983). Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans. Antimicrobial Agents and Chemotherapy 23,185-7.
25. Whelan, W. L, Simon, S., Beneke, E. S. & Rogers, A. L. (1984). Auxotrophic variants of Torulopsis glabrata. FEMS Microbiology Letters 24, 1-4.
26. Fasoli, M. & Kerridge, D. (1988). Isolation and characterization of fluoropyrimidine-resistant mutants in two Candida species. Annals of the New York Academy of Science 544,260-3.
27. Whelan, W. L. & Magee, P. T. (1981). Natural heterozygosity in Candida albicans. Journal of Bacteriology 145,896-903.
28. Berenbaum, M. C. (1978). A method for testing for synergy with any number of agents. Journal of Infectious Diseases 137,122-30.
29. Siau, H. (1992). The effects of antifungal drugs in combination on the growth of Candida species. Ph.D. thesis, University of Cambridge.
30. McCammon, M. T. & Park, L. W. (1981). Inhibition of sterol transmethylation by S-adenosyl-homocysteine analogs. Journal of Bacteriology145,106-12.
31. Margalith, P. Z. (1986). Steroid Microbiology. Charles C. Thomas, Springfield, IL, USA.
32. Vanden Bossche, H., Marichal, P., Gorrens, J., Bellens, D., Coene, M., Lauwers, W. ef al. (1990). Mode of action of antifungals of use in immunocompromised patients. Focus on Candida glabrata and Histoplasma capsulatum. In Mycoses in AIDS Patients (Vanden Bossche, H., Mackenzie, D. W. R., Cauwenbergh, G., Cutsem, J. V., Drouhet, E. & Dupont, B., Eds), p. 233-43. Plenum Press, New York.
33. Fasoli, M. O. F. & Kerridge, D. (1990). Uptake of pyrimidines and their derivatives into Candida glabrata and Candida albicans. Journal of General Microbiology 136,1475-81.
34. Larsen, R. A., Bozzette, S. A., Jones, B. E., Haghighat, D., Leal, M. A., Forthal, D. et al. (1994). Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases 19,741-5.
35. Sugar, A. M. (1995). Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrobial Agents and Chemotherapy 39,1907-12.
36. Ghannoum, M. A., Rex, J. H. & Galgiani, J. N. (1996). Susceptibility testing of fungi: current status of correlation of in-vitro data with clinical outcome. Journal of Clinical Microbiology 34, 489-95.